Want to see LGND full AI Analyst Report?
LGND Stock Chart & Stats
$280.18
-$1.62(-0.54%)
At close: 4:00 PM EDT
$280.18
-$1.62(-0.54%)
Day’s Range― - ―
52-Week Range$175.89 - $326.63
Previous CloseN/A
Volume277.03K
Average Volume (3M)251.76K
Market Cap
$6.28B
Enterprise Value$6.68B
Total Cash (Recent Filing)$1.36B
Total Debt (Recent Filing)$1.13B
Price to Earnings (P/E)31.4
Beta0.93
Next Earnings
Oct 29, 2026EPS Estimate
2.33Next Dividend Ex-DateN/A
Dividend Yield5.35%
Share Statistics
EPS (TTM)10.01
Shares Outstanding19,935,610
10 Day Avg. Volume221,152
30 Day Avg. Volume251,758
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue22.98
Enterprise Value/Gross Profit23.31
Enterprise Value/Ebitda24.36
Forecast
1Y Price Target
$362.83Price Target Upside29.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)9.35
Revenue Forecast (FY)$289.47M
Bulls Say, Bears Say
Bulls Say
Royalty-model ProfitabilityLigand’s licensing and royalty model supports very high margins because partners carry much of the development and commercial infrastructure. This capital-efficient structure can convert growing partner sales into durable operating profit and cash generation over the next several quarters.
Expanded Royalty PortfolioThe XOMA acquisition materially broadens Ligand’s asset base and increases exposure to commercial and late-stage products. Greater portfolio depth and longer royalty duration can reduce reliance on individual programs while creating multiple avenues for sustained royalty and milestone growth.
Partnered Revenue MomentumStrong royalty growth from multiple partnered products demonstrates that Ligand’s portfolio is producing meaningful commercial traction. Continued adoption of partner medicines can provide an expanding revenue base without requiring Ligand to build a large direct sales organization.
Bears Say
Higher LeverageDebt now exceeds equity after a meaningful increase in leverage, raising financial risk compared with Ligand’s historically more conservative profile. Although current cash generation is strong, higher obligations can constrain acquisition capacity and reduce resilience if earnings or royalties normalize lower.
Volatile Cash ConversionHealthy current operating and free cash flow is tempered by a history of substantial variability, showing that cash conversion is not consistently predictable. Such swings can complicate capital planning and make funding acquisitions or obligations more dependent on the timing of partner payments.
Clinical And Regulatory Execution RiskLigand’s expanded development portfolio offers upside but remains exposed to binary clinical outcomes across several pivotal programs. Failed readouts or delays could reduce milestone receipts, postpone future royalties, and weaken the expected economic contribution from assets not yet commercially validated.
Ligand Pharma News
LGND FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was $175.89 and its highest was $326.63 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is $6.28B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Aug 06, 2026. The company reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.36.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of $0.456 which represents an annual dividend yield of 5.35%. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 2.33.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,935,610 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of $2.37 in its last earnings report, beating expectations of $2.01. Following the earnings report the stock price went down -0.803%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in LGND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$362.83 (29.50% Upside)
$362.83 (29.50% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 63%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 8.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.87%
12-Months-Change
Fundamentals
Return on Equity
20.06%
Trailing 12-Months
Asset Growth
130.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum: robust top-line and EPS growth, significant cash flow generation, completion of an accretive and scalable acquisition (XOMA), and successful low-cost financing that materially strengthens capital flexibility. Manageable near-term challenges include a product sales decline (Kyprolis), one-time charges, accounting complexity from increased financial royalty assets, and some timing risk from an FDA recommendation requiring a Phase III for PSC. On balance, the company presented multiple clear growth drivers and disciplined capital deployment that outweigh the identified risks.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$362.83
▲(29.50% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Xencor
―
Zymeworks
―
AbCellera Biologics
―
Ownership Overview
2.50% Insiders
46.26% Mutual Funds
4.56% Other Institutional Investors
18.27% Public Companies and
Individual Investors